Cutaneous small vessel vasculitis

WikiDoc Resources for Cutaneous small vessel vasculitis
Articles
Most recent articles on Cutaneous small vessel vasculitis Most cited articles on Cutaneous small vessel vasculitis Review articles on Cutaneous small vessel vasculitis Articles on Cutaneous small vessel vasculitis in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Cutaneous small vessel vasculitis Images of Cutaneous small vessel vasculitis Photos of Cutaneous small vessel vasculitis Podcasts & MP3s on Cutaneous small vessel vasculitis Videos on Cutaneous small vessel vasculitis
Evidence Based Medicine
Cochrane Collaboration on Cutaneous small vessel vasculitis Bandolier on Cutaneous small vessel vasculitis TRIP on Cutaneous small vessel vasculitis
Clinical Trials
Ongoing Trials on Cutaneous small vessel vasculitis at Clinical Trials.gov Trial results on Cutaneous small vessel vasculitis Clinical Trials on Cutaneous small vessel vasculitis at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Cutaneous small vessel vasculitis NICE Guidance on Cutaneous small vessel vasculitis NHS PRODIGY Guidance FDA on Cutaneous small vessel vasculitis CDC on Cutaneous small vessel vasculitis
Books
Books on Cutaneous small vessel vasculitis
News
Cutaneous small vessel vasculitis in the news Be alerted to news on Cutaneous small vessel vasculitis News trends on Cutaneous small vessel vasculitis
Commentary
Blogs on Cutaneous small vessel vasculitis
Definitions
Definitions of Cutaneous small vessel vasculitis
Patient Resources / Community
Patient resources on Cutaneous small vessel vasculitis Discussion groups on Cutaneous small vessel vasculitis Patient Handouts on Cutaneous small vessel vasculitis Directions to Hospitals Treating Cutaneous small vessel vasculitis Risk calculators and risk factors for Cutaneous small vessel vasculitis
Healthcare Provider Resources
Symptoms of Cutaneous small vessel vasculitis Causes & Risk Factors for Cutaneous small vessel vasculitis Diagnostic studies for Cutaneous small vessel vasculitis Treatment of Cutaneous small vessel vasculitis
Continuing Medical Education (CME)
CME Programs on Cutaneous small vessel vasculitis
International
Cutaneous small vessel vasculitis en Espanol Cutaneous small vessel vasculitis en Francais
Business
Cutaneous small vessel vasculitis in the Marketplace Patents on Cutaneous small vessel vasculitis
Experimental / Informatics
List of terms related to Cutaneous small vessel vasculitis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Jesus Rosario Hernandez, M.D. [2].

Synonyms and keywords: Cutaneous leukocytoclastic angiitis, cutaneous leukocytoclastic vasculitis, cutaneous necrotizing venulitis, hypersensitivity angiitis.

Overview

Cutaneous small-vessel vasculitis (also known as "Cutaneous leukocytoclastic angiitis," "Cutaneous leukocytoclastic vasculitis," "Cutaneous necrotizing venulitis," and "Hypersensitivity angiitis") is inflammation of small blood vessels (usually post-capillary venules in the dermis), characterized by palpable purpura. It is the most common vasculitis seen in clinical practice. Leukocytoclasis refers to the damage caused by nuclear debris from infiltrating neutrophils in and around the vessels.

Subtypes of small-vessel vasculitis include:

Historical Perspective

• [Disease name] was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
• In [year], [gene] mutations were first identified in the pathogenesis of [disease name].
• In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name].

Classification

• [Disease name] may be classified according to [classification method] into [number] subtypes/groups:

• [group1]
• [group2]
• [group3]

• Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3].

Pathophysiology

• The pathogenesis of [disease name] is characterized by [feature1], [feature2], and [feature3].
• The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway.
• On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
• On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].

Causes

• [Disease name] may be caused by either [cause1], [cause2], or [cause3].
• [Disease name] is caused by a mutation in the [gene1], [gene2], or [gene3] gene[s].
• There are no established causes for [disease name].

Differentiating [disease name] from other Diseases

• [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:

• [Differential dx1]
• [Differential dx2]
• [Differential dx3]

Epidemiology and Demographics

• The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
• In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].

Age

• Patients of all age groups may develop [disease name].

• [Disease name] is more commonly observed among patients aged [age range] years old.
• [Disease name] is more commonly observed among [elderly patients/young patients/children].

Gender

• [Disease name] affects men and women equally.

• [Gender 1] are more commonly affected with [disease name] than [gender 2].
• The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.

Race

• There is no racial predilection for [disease name].

• [Disease name] usually affects individuals of the [race 1] race.
• [Race 2] individuals are less likely to develop [disease name].

Risk Factors

• Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

Natural History, Complications and Prognosis

• The majority of patients with [disease name] remain asymptomatic for [duration/years].
• Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
• If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
• Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
• Prognosis is generally [excellent/good/poor], and the [1/5/10­year mortality/survival rate] of patients with [disease name] is approximately [#%].

Diagnosis

Diagnostic Criteria

• The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:

• [criterion 1]
• [criterion 2]
• [criterion 3]
• [criterion 4]

Symptoms

• [Disease name] is usually asymptomatic.
• Symptoms of [disease name] may include the following:

• [symptom 1]
• [symptom 2]
• [symptom 3]
• [symptom 4]
• [symptom 5]
• [symptom 6]

Physical examination

Gallery

Skin

Extremities

• 

  url = http://www.atlasdermatologico.com.br/disease.jsf?diseaseId=484>
  

• 

  url = http://www.atlasdermatologico.com.br/disease.jsf?diseaseId=484>
  

• 

  url = http://www.atlasdermatologico.com.br/disease.jsf?diseaseId=484>
  

• 

  url = http://www.atlasdermatologico.com.br/disease.jsf?diseaseId=484>
  

• 

  url = http://www.atlasdermatologico.com.br/disease.jsf?diseaseId=484>
  

• 

  url = http://www.atlasdermatologico.com.br/disease.jsf?diseaseId=447>
  

• 

  url = http://www.atlasdermatologico.com.br/disease.jsf?diseaseId=447>
  

• 

  url = http://www.atlasdermatologico.com.br/disease.jsf?diseaseId=447>
  

• 

  url = http://www.atlasdermatologico.com.br/disease.jsf?diseaseId=447>
  

• 

  url = http://www.atlasdermatologico.com.br/disease.jsf?diseaseId=447>
  

Trunk

• 

  url = http://www.atlasdermatologico.com.br/disease.jsf?diseaseId=484>
  

Laboratory Findings

• There are no specific laboratory findings associated with [disease name].

• A [positive/negative] [test name] is diagnostic of [disease name].
• An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
• Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

Imaging Findings

• There are no [imaging study] findings associated with [disease name].

• [Imaging study 1] is the imaging modality of choice for [disease name].
• On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
• [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

• [Disease name] may also be diagnosed using [diagnostic study name].
• Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].

Treatment

Medical Therapy

• There is no treatment for [disease name]; the mainstay of therapy is supportive care.

• The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
• [Medical therapy 1] acts by [mechanism of action 1].
• Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].

Surgery

• Surgery is the mainstay of therapy for [disease name].
• [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
• [Surgical procedure] can only be performed for patients with [disease stage] [disease name].

Prevention

• There are no primary preventive measures available for [disease name].

• Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].

• Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].